LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (OTCBB:CGRB) today announced that positive Phase I data on the Company’s prostate cancer drug candidate CB7630 (abiraterone acetate) was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is currently taking place in San Francisco, California. The data was presented today in a poster presentation as part of the poster session on hormonal therapy. The poster presentation is further detailed below:
